Hikma Pharmaceuticals PLC
HKMPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 22.32 | -0.41 | -30.25 |
| FCF Yield | 5.94% | 8.00% | 7.38% | 5.88% |
| EV / EBITDA | 9.15 | 10.80 | 7.48 | 9.63 |
| Quality | ||||
| ROIC | 12.78% | 7.16% | 6.53% | 12.92% |
| Gross Margin | 45.25% | 48.94% | 49.19% | 50.96% |
| Cash Conversion Ratio | 1.24 | 2.16 | 2.27 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.50% | 4.04% | 2.45% | 4.97% |
| Free Cash Flow Growth | -18.56% | 32.46% | -25.43% | 70.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.54 | 1.76 | 1.47 | 0.55 |
| Interest Coverage | 6.95 | 4.22 | 4.03 | 8.43 |
| Efficiency | ||||
| Inventory Turnover | 1.74 | 1.65 | 1.65 | 1.80 |
| Cash Conversion Cycle | 239.53 | 244.88 | 251.08 | 238.32 |